ONIVYDE PEGYLATED LIPOSOMAL 4,3 mg/ml, dispersion à diluer pour perfusion

( ARTG ) ONIVYDE is indicated:, in combination with oxaliplatin and 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of metastatic pancreatic adenocarcinoma., in combination with 5-FU and LV for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.